Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Public ClinicalTrials.gov record NCT04824092. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL
Study identification
- NCT ID
- NCT04824092
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 899 participants
Conditions and interventions
Conditions
Interventions
- Tafasitamab Drug
- Lenalidomide Drug
- Rituximab Drug
- Cyclophosphamide Drug
- Doxorubicin Drug
- Vincristine Drug
- Prednisone Drug
- Tafasitamab placebo Drug
- Lenalidomide placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 11, 2021 (Actual)
- Primary completion
- Sep 1, 2026 (Estimated)
- Completion
- Nov 1, 2027 (Estimated)
- Last update posted
- Apr 1, 2026
2021 – 2027
United States locations
- U.S. sites
- 47
- U.S. states
- 23
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MorphoSys Research Site | Daphne | Alabama | 36526 | — |
| MorphoSys Research Site | Anaheim | California | 92801 | — |
| MorphoSys Research Site | Clovis | California | 93611 | — |
| MorphoSys Research Site | Fullerton | California | 92834-4138 | — |
| MorphoSys Research Site | Harbor City | California | 90710 | — |
| MorphoSys Research Site | Los Angeles | California | 90017 | — |
| MorphoSys Research Site | San Diego | California | 92123 | — |
| MorphoSys Research Site | Whittier | California | 90603 | — |
| MorphoSys Research Site | Aurora | Colorado | 80012 | — |
| MorphoSys Research Site | Jacksonville | Florida | 32224 | — |
| MorphoSys Research Site | Honolulu | Hawaii | 96813 | — |
| MorphoSys Research Site | Wichita | Kansas | 67214 | — |
| MorphoSys Research Site | Lexington | Kentucky | 40536-0293 | — |
| MorphoSys Research Site | Louisville | Kentucky | 40241 | — |
| MorphoSys Research Site | Baltimore | Maryland | 21237 | — |
| MorphoSys Research Site | Bethesda | Maryland | 20817-7847 | — |
| MorphoSys Research Site | Columbia | Maryland | 21044 | — |
| MorphoSys Research Site | Detroit | Michigan | 48202 | — |
| MorphoSys Research Site | Minneapolis | Minnesota | 55426 | — |
| MorphoSys Research Site | Rochester | Minnesota | 55905 | — |
| MorphoSys Research Site | Kansas City | Missouri | 64132 | — |
| MorphoSys Research Site | Lebanon | New Hampshire | 03755 | — |
| MorphoSys Research Site | Florham Park | New Jersey | 07932 | — |
| MorphoSys Research Site | Buffalo | New York | 14263 | — |
| MorphoSys Research Site | Rochester | New York | 14642 | — |
| MorphoSys Research Site | Canton | Ohio | 44718 | — |
| MorphoSys Research Site | Cincinnati | Ohio | 45242 | — |
| MorphoSys Research Site | Eugene | Oregon | 97401 | — |
| MorphoSys Research Site | Danville | Pennsylvania | 17822-4910 | — |
| MorphoSys Research Site | Chattanooga | Tennessee | 37404 | — |
| MorphoSys Research Site | Germantown | Tennessee | 38138 | — |
| MorphoSys Research Site | Nashville | Tennessee | 37203 | — |
| MorphoSys Research Site | Austin | Texas | 78745 | — |
| MorphoSys Research Site | Bedford | Texas | 76022 | — |
| MorphoSys Research Site | Denison | Texas | 75020 | — |
| MorphoSys Research Site | Fort Worth | Texas | 76104 | — |
| MorphoSys Research Site | Houston | Texas | 77030 | — |
| MorphoSys Research Site | McAllen | Texas | 78503 | — |
| MorphoSys Research Site | Tyler | Texas | 75702 | — |
| MorphoSys Research Site | Ogden | Utah | 84405 | — |
| MorphoSys Research Site | Salt Lake City | Utah | 84112 | — |
| MorphoSys Research Site | Gainesville | Virginia | 20155 | — |
| MorphoSys Research Site | Roanoke | Virginia | 24014 | — |
| MorphoSys Research Site | Virginia Beach | Virginia | 23456 | — |
| MorphoSys Research Site | Olympia | Washington | 98502 | — |
| MorphoSys Research Site | Tacoma | Washington | 98405 | — |
| MorphoSys Research Site | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 260 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04824092, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 1, 2026 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04824092 live on ClinicalTrials.gov.